<DOC>
	<DOCNO>NCT01419834</DOCNO>
	<brief_summary>The purpose study find `` humanize 3F8 '' ( Hu3F8 ) safe treat neuroblastoma cancer . A phase 1 study mean investigator try find side effect happen high high dos drug use . The investigator want find effect , good and/or bad , Hu3F8 cancer . The amount Hu3F8 patient get depend start treatment study . The investigator also want find Hu3F8 work effective attack disease . Hu3F8 experimental drug , mean yet approve FDA treatment disease .</brief_summary>
	<brief_title>Humanized 3F8 Monoclonal Antibody ( Hu3F8 ) Patients With High-Risk Neuroblastoma GD2-Positive Tumors</brief_title>
	<detailed_description>Patients treat 2 different schedule : For patient follow 2 doses/cycle schedule ( patient enrol start treatment prior Amendment A ( 8 ) ) , one cycle 2 day intravenous hu3F8 treatment , give approximately 7 day apart . For patient follow 3 doses/cycle schedule , one cycle 3 day intravenous hu3F8 treatment , give day 1 , 3 5 . After Cycle 1 , patient may receive treatment modify schedule 3 day intravenous hu3F8 10 day , need . To limit side-effects , patient receive analgesic antihistamine premedications . Cycles 21 day repeat total 12 cycle , see section 9.1 detail . Evaluations , treatment summarize Tables 4A B . In addition , study side effect pain , patient ask assess pain day treatment hu3F8 3 different time point : ( ) prior commencement hu3F8 , ( b ) least acute pain episode rescue pain medication dose usually require ( c ) prior discharge Pediatric Day Hospital .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must either ( 1 ) diagnosis NB define international criteria,56 i.e. , histopathology ( confirm MSKCC Department Pathology ) BM metastases plus high urine catecholamine level , ( 2 ) tumor GD2positive immunostaining m3F8 . °A nonNB tumor define GD2positive immunostaining m3F8 . If fresh frozen tumor available immunostaining , patient consider eligible publish report show &gt; 50 % tumor type GD2positive immunohistochemistry . ( Note : Tissues must fresh/frozen fix , paraffinembedded specimen unsuitable antiGD2 immunostaining ) . Tumors know GD2positive criterion need immunostaining . These include : Melanoma ( &gt; 50 % ) , Desmoplastic small round cell tumor ( 70 % ) , Osteosarcoma ( 88 % ) Soft tissue sarcoma include liposarcoma , fibrosarcoma , malignant fibrous histiocytoma , leiomyosarcoma , spindle cell sarcoma ( 93 % ) . Patients must either ( 1 ) refractory relapse highrisk NB ( include MYCNamplified stage 3/4/4S MYCNnonamplified stage 4 patient great 18 month age ) resistant standard therapy , ( 2 ) refractory relapse GD2positive tumor . Patients must older 1 year age . Prior treatment murine 3F8 allow . Patients prior m3F8 ch14.18 treatment must HAHA antibody titer less upper limit normal [ define mean + 3*SD normal volunteer ] . Negative serum pregnancy test woman childbearing potential . Women childbearing potential must willing practice effective method birth control treatment Signed informed consent indicate awareness investigational nature program . Existing major organ dysfunction &gt; grade 2 , exception hearing loss myelosuppression define suppression type WBCs , RBCs platelet ) . However , follow parameter must meet : white blood cell count ≥1000/ul , absolute ( neutrophil count ≥500/ul absolute lymphocyte count ≥500/ul platelet count ≥ 25,000/ul Active lifethreatening infection . Pregnant woman woman breastfeed . Inability comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CNS</keyword>
	<keyword>Brain</keyword>
	<keyword>MAB 3F8</keyword>
	<keyword>Hu3F8</keyword>
	<keyword>11-009</keyword>
</DOC>